Dynaglipt L 5mg Tablet

Introduction

Dynaglipt L is a prescription medication that contains the active ingredient Linagliptin. It is available in tablet form and is commonly prescribed to treat type 2 diabetes mellitus in adults.

Uses

Dynaglipt L is primarily used to help control blood sugar levels in individuals with type 2 diabetes. It is often prescribed alongside a healthy diet and exercise program to improve glycemic control.

Dosage and Administration

The recommended dosage of Dynaglipt L may vary depending on individual factors such as age, weight, and the severity of the condition. Follow your healthcare provider’s instructions regarding dosage. Typically, the medication is taken orally once a day with or without food.

Mechanism of Action

Linagliptin, the active ingredient in Dynaglipt L, belongs to a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the levels of incretin hormones in the body. These hormones help to regulate blood sugar levels by stimulating the release of insulin and decreasing the production of glucose in the liver.

Side Effects

Common side effects may include headache, upper respiratory tract infection, and nasopharyngitis. These side effects are generally mild and tend to resolve on their own. However, if they persist or worsen, consult your healthcare provider.

In rare cases, Dynaglipt L may cause serious side effects such as pancreatitis or allergic reactions. Seek immediate medical attention if you experience symptoms such as severe abdominal pain, persistent nausea or vomiting, or signs of an allergic reaction such as rash, itching, or swelling.

Drug Interactions

inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products. Dynaglipt L may interact with certain medications, including other antidiabetic agents, which could affect blood sugar control. Your healthcare provider will consider potential drug interactions before prescribing Dynaglipt L.

Precautions

Before taking Dynaglipt L, inform your healthcare provider about any medical conditions you have, especially if you have a history of pancreatitis or severe allergic reactions. Additionally, let your healthcare provider know if you are pregnant, planning to become pregnant, or breastfeeding.

Dynaglipt L may not be suitable for everyone. It is contraindicated in individuals with a known hypersensitivity to Linagliptin or any of the other ingredients in the medication. Your healthcare provider will assess the potential risks and benefits before prescribing Dynaglipt L.

Storage

Dynaglipt L should be stored at room temperature, away from moisture and heat. Keep the medication out of the reach of children and pets. Do not use Dynaglipt L if it has expired or if the tablets appear damaged or discolored.

Patient Tips

• Take Dynaglipt L exactly as prescribed by your healthcare provider.
• Follow a healthy diet and exercise program as recommended by your healthcare provider.
• Monitor your blood sugar levels regularly and report any significant changes to your healthcare provider.
• If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and resume your regular dosing schedule.
• If you have any questions or concerns about Dynaglipt L, consult your healthcare provider for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Linagliptin: medicine to treat type 2 diabetes (NHS UK) [Accessed 10 Jun. 2024] (online) Available at:
• Glyxambi 10 mg/5 mg Film-coated Tablets (Health Professionals SmPC) Available at:
• Linagliptin (Drugs.com) [Accessed 15 Jun. 2024] (online) Available at:
• linagliptin (RX) [Accessed 5 Jun. 2024] (online) Available at:
• Linagliptin (MedlinePlus) [Accessed 4 Jun. 2024] (online) Available at:
• Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. [Accessed 20 Jun. 2024] Available at: